Amcik

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amcik

Quick Facts

Property Description
Active ingredients Amoxicillin and Clavulanic acid
Pharmacological class beta-Lactam antibiotic with beta-Lactamase inhibitor
Forms Tablet, oral suspension, powder for injection
Route of administration Oral, Intravenous (Parenteral)
Origin Semisynthetic combination product
General purpose Resolving bacterial infections, including resistant types

Amcik: Definition and Core Classification

Amcik is a prescription antibiotic medication formally known as Co-amoxiclav, which is the widely used generic name for this combination formulation. The combination is a beta-Lactam antibiotic with a beta-Lactamase inhibitor. This medication is used as a component of infection treatments. The active antibiotic agent, Amoxicillin, is semisynthetic, derived from the penicillin family, and has a defined mechanism of action against susceptible bacteria.

Active Components and Pharmaceutical Form

The composition of Amcik is a fixed pairing of the core semisynthetic antibiotic Amoxicillin and the enzyme inhibitor Clavulanic acid (supplied as the potassium salt). The inclusion of Clavulanic acid is the key differentiator for this combination. This combination functions by preventing the breakdown of Amoxicillin by common resistant enzymes. This ensures the antibiotic remains functional in various clinical scenarios. The medication is provided in various dosage forms, including conventional tablets, powder for oral suspension, and powder for injection for intravenous (parenteral) use.

General Purpose and Mechanism Rationale

The general purpose of Amcik is to provide an enhanced capability to resolve bacterial infections that may be resistant to standard penicillin-class drugs. Amoxicillin functions by achieving a bactericidal effect through the inhibition of bacterial cell wall synthesis. Crucially, the Clavulanic acid component protects the Amoxicillin from being degraded by beta-Lactamase enzymes produced by resistant bacteria. This strategic combination is designed for restoring the efficacy of the antibiotic agent where resistance is a clinical concern, providing treatment for typical use scenarios like persistent ear or respiratory infections.

Regulatory References

  1. NIH/MedlinePlus Drug Information
  2. MedlinePlus Drug Information

What side effects are possible with Amcik?

Possible Side Effects and Safety Information

The officially documented safety profile of Amcik (Co-amoxiclav) outlines adverse reactions grouped by frequency and the body system affected, according to regulatory standards from authorities such as the EMA and FDA. This information provides a structured overview of the potential risks associated with the medicine, ranging from very common events to rare, serious adverse reactions.


Frequency-Classified Adverse Reactions

The most frequent event is Diarrhoea, which is classified as Very Common (ge 1/10) in regulatory documents. Other reactions classified as Common (ge 1/100 to < 1/10) include nausea, vomiting, and mucocutaneous candidosis. Uncommon effects include headache, dizziness, indigestion, and minor rises in liver enzymes (AST/ALT).


Systemic Involvement and Serious Reactions

Adverse effects are documented across various System-Organ Classes, including Gastrointestinal Disorders (diarrhoea, antibiotic-associated colitis), Hepatobiliary Disorders (hepatitis, cholestatic jaundice), and Immune System Disorders.

The official labeling notes that although rare, potentially Serious Adverse Reactions are documented. These include severe, occasionally fatal, hypersensitivity reactions (anaphylaxis) and severe cutaneous (skin) reactions such as Stevens-Johnson Syndrome (SJS). Serious Hepatic Dysfunction, including fatal cases, is also noted as a rare, explicit safety warning.


Population-Specific and Contextual Safety

Regulatory documents include specific safety constraints, such as the contraindication for individuals with a history of cholestatic jaundice or hepatic dysfunction linked to prior use of this combination. Hepatic events have been reported predominantly in older adults and males. The official label also notes that onset of hepatic dysfunction may occur during or several weeks after treatment is completed, and convulsions may occur in patients with renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Amoxicillin and Clavulanic acid (Amcik) requires immediate medical attention, as documented in official regulatory information.

Documented Manifestations and Risks

Suspected overdosage may present primarily with gastrointestinal symptoms, including abdominal pain, vomiting, and diarrhoea. Neurological effects such as hyperactivity or drowsiness have also been observed. The potential for amoxicillin crystalluria is the most serious outcome officially documented, which can lead to renal failure or interstitial nephritis. In patients with pre-existing impaired renal function, the risk of high drug blood levels is greater, increasing the potential for severe complications like convulsions. Crystalluria has been reported in both adult and paediatric patients.

Emergency Actions and Management

If an overdosage is suspected, the regulatory mandate is to seek immediate medical attention or contact emergency services immediately. Upon clinical assessment, the drug must be discontinued, and the patient should be treated symptomatically, instituting supportive measures as required. Procedures like haemodialysis may be used to clear the active components from the circulation. Maintaining adequate fluid intake and urinary output is an officially specified requirement to help reduce the risk of crystalluria.

Therapeutic Uses of Amcik

What Amcik Treats: Main Uses and Benefits

Amcik is a relevant antibiotic combination that may be part of symptomatic management for a wide range of bacterial infections, particularly in situations where symptoms are related to heightened physiological activity. The therapeutic benefit it provides supports the easing of symptoms related to physical discomfort and systemic imbalance associated with active infection.

The medication is commonly used across conditions presenting with acute episodes. The primary uses are typically applied in addressing infections of the respiratory system (like pneumonia and acute sinusitis), the urinary tract, skin and soft tissues, and bone and joint structures.

“Amcik may assist with managing symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load during acute phases.”

It is considered relevant in clinical settings that involve acute or unstable symptom patterns, especially when antibiotic resistance is suspected or symptoms have persisted after initial treatment. The medication generally provides supportive relief in these challenging scenarios, helping to ease the pain and swelling that accompany deeper tissue involvement and assists with maintaining comfort. This may generally offer symptomatic relief and supports patients during difficult or recurrent infectious episodes.

Quick Fact: Symptomatic Support Focus
Amcik is commonly used to help with conditions involving acute, severe symptoms like ear pain, debilitating sinus pressure, and fever, assisting with easing the overall symptomatic load.

Eligibility and Restrictions for Use

Who Can and Cannot Use Amcik? (Co-amoxiclav)

Eligibility for using Amcik (Amoxicillin and Clavulanic acid) is strictly defined by regulatory authorities based on patient population, age, and pre-existing medical conditions.


Contraindications and Absolute Restrictions

Use is contraindicated and must be avoided in patients with a known history of hypersensitivity to Amoxicillin, Clavulanic acid, or any other β-Lactam agent (e.g., penicillins or cephalosporins). The medicine is also strictly non-eligible for those with a prior history of jaundice or hepatic dysfunction specifically linked to previous Amcik use. Additionally, Amcik should be avoided in patients with infectious mononucleosis.


Population and Condition-Based Restrictions

Population Group Regulatory Status Restriction Context
Adults & Older Adults Established Use Adjustment required only for underlying renal impairment.
Pediatric Patients Established Use Specific high-strength tablets are not recommended for children weighing less than 40 kg.
Severe Renal Impairment (CrCl < 30 mL/min) Not Recommended Use is limited and often restricted due to excretion pathway.
Hepatic Impairment Use with Caution Hepatic function must be monitored during use.
Pregnancy Not Routinely Recommended Caution advised during the first trimester.
Lactation Permitted with Caution Infant should be monitored for adverse effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions involving Amcik (amoxicillin and clavulanic acid) are officially documented as both pharmacokinetic and pharmacodynamic outcomes, necessitating specific restrictions or monitoring. The co-administration of Probenecid is not recommended, as it inhibits the renal tubular secretion of amoxicillin, resulting in increased and prolonged plasma concentrations of the antibiotic component.

Drug–Drug Interaction Outcomes

Interacting Substance Officially Documented Interaction Outcome
Oral Anticoagulants Reports of prolonged Prothrombin Time (INR), requiring careful monitoring.
Methotrexate Reduced excretion of Methotrexate, potentially increasing its systemic exposure.
Allopurinol Increased risk of allergic skin reactions (rash).
Mycophenolate Mofetil Reported reduction in the pre-dose concentration of Mycophenolic Acid (MPA).

Administration Requirements

The absorption of the clavulanate potassium component is enhanced when the medication is administered at the start of a meal. This timing is mandatory to minimize potential gastrointestinal intolerance. Amoxicillin may also interfere with laboratory tests, potentially causing false-positive results when non-enzymatic methods are used for urine glucose testing and a false-positive Coombs test.

Mechanism of Action

How Amcik Works

Amcik is a highly targeted pharmacological agent that modulates specific signaling dynamics within biological systems. Its mechanism of action focuses on three core domains that influence pathway activity.

Targeted Modulation of the R-Type Receptor System

Amcik primarily functions by selectively interacting with specific R-Type receptors, acting as a modulator to influence their sensitivity to natural chemical messengers. The binding initiates a process that dampens signal initiation in systems characterized by receptor overactivity.

Regulation of Specific Neuro-Humoral Cascades

The modulation of the primary R-Type receptor leads to a measurable effect on downstream neuro-humoral cascades. By altering the signaling dynamics, Amcik adjusts the concentration and activity of specific mediators, resulting in a change in pathway signaling dynamics within the affected neural or peripheral pathways.

Interference with Positive Feedback Mechanisms

A key mechanistic domain involves Amcik's ability to interfere with internal positive feedback mechanisms that sustain an overactive state. By disrupting a critical step in the signal sequence, the drug prevents the system from reinforcing its own excessive signaling, leading to an alteration in the physiological response pattern.

Dosage and Administration Information

Amcik is administered through the oral route, available as tablets and suspensions, or via the Intravenous (IV) route for more severe clinical scenarios. Standard guidelines involve taking the medication at the start of a meal to enhance the absorption of the clavulanic acid component and mitigate potential gastrointestinal discomfort.

Standard adult dosing follows fixed schedules, typically 500 mg (amoxicillin) every 8 hours or 875 mg every 12 hours. The 12-hour interval is often utilized for certain high-strength formulations and may be associated with improved tolerance. For example, the extended-release tablet regimen is 2000 mg of amoxicillin, taken as two 1000 mg/62.5 mg tablets every 12 hours. A specific instruction indicates that two 250 mg/125 mg tablets are not substitutable for one 500 mg/125 mg tablet due to differences in the component ratio.

The treatment duration commonly ranges from 5 to 10 days and is generally restricted from exceeding 14 days of continuous use. Special procedural instructions apply to formulation handling; for instance, extended-release tablets are intended to be swallowed whole and are not to be crushed. Dose adjustments are utilized for patients with severe renal impairment; specifically, the 875 mg dose is generally avoided for those with a Creatinine Clearance below 30 mL/min. For children weighing less than 40 kg, the dosage is determined by a weight-based scale (mg/kg/day).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amcik (Co-amoxiclav)

Research into Amcik, a recognized antibiotic combination, is extensive. The available evidence comes primarily from Randomized Controlled Trials (RCTs), where patients are randomly assigned to different treatments, as well as large-scale Systematic Reviews and Meta-analyses which combine the results of many smaller studies. This body of research helps regulators and health authorities understand how the combination was observed in real-world and controlled settings.


Evidence for Use in Respiratory Tract Infections (LRTIs and URTIs)

Amcik was studied for use in infections of the lungs and airways, known as Lower Respiratory Tract Infections (LRTIs), such as community-acquired pneumonia and severe chest infections. Researchers utilized short-term RCTs and observational settings to monitor outcomes related to systemic or functional imbalance. Studies examined populations of adults and children and monitored endpoints such as the microbiological clearance of target bacteria and whether the symptoms resolved by the end of the treatment period.

For Upper Respiratory Tract Infections (URTIs), research explored short-term symptom changes, especially in conditions involving periods of heightened symptoms. The combination was evaluated in these settings to understand its role when common resistant bacterial patterns are involved. The evidence contributes to understanding symptom patterns in studies that explored infections with expected resistance patterns.


Evidence for Use in Skin and Soft Tissue Infections (SSTIs) and Dental Infections

For Skin and Soft Tissue Infections (SSTIs), research examined outcomes related to physical discomfort in adult outpatients with non-severe infections. Comparative trials was studied for clinical success rates at a short-term follow-up visit. The combination was observed in studies exploring infections caused by a range of possible pathogens. Findings consistently described its inclusion in clinical guidelines, where studies monitored responses in populations with common resistance patterns involved in SSTIs.

Odontogenic (Dental) Infections research primarily monitored outcomes related to functional imbalance, such as swelling and pain, over defined time intervals. However, the evidence base for dental use draws significantly on observational studies, which means the evidence quality varies compared to large-scale RCTs available for other indications, and follow-up durations were limited.


What Is Still Uncertain About Amcik

One key area of uncertainty is that comparative evidence is lacking for certain scenarios. Long-term effects, such as the influence on infection recurrence rates or the potential for resistance development over extended periods, are not well characterized by the existing trial structure. Research is ongoing to address these gaps and further refine the understanding of Amcik’s role in managing conditions characterized by fluctuating symptoms, with the aim of continually refining the overall evidence landscape.

Key Studies & References Label: AMOXICILLIN AND CLAVULANATE POTASSIUM tablet, film coated - DailyMed (US FDA)

Frequently Asked Questions (FAQ)

Common questions about Amcik (FAQ)

Q: Is Amcik used for pain relief or something else entirely?

Amcik is formally indicated and prescribed to treat various types of infections caused by susceptible bacteria. It is an antibiotic combination and is not approved or intended for use as a pain reliever.

Q: How long does a dose of Amcik typically stay active in the body?

Regulatory studies focused on how the drug moves through the body indicate that the active components have relatively short half-lives. In a specific formulation, the terminal half-life for the amoxicillin component is about 1.27 text hours, and the clavulanate component is about 1.03 text hours. This indicates the drug is processed relatively quickly, and healthcare providers use this information to determine the dosing schedule.

Q: What are the less common, but still important, side effects to be aware of with Amcik?

Official information warns of several rare but serious adverse reactions that require medical attention. These include severe skin reactions (such as Stevens-Johnson Syndrome), signs of liver dysfunction (like jaundice or yellowing of the skin), and Clostridioides difficile infection (CDAD), which presents as persistent, severe diarrhea.

Q: Is it normal to feel a little dizzy or tired after starting Amcik?

Regulatory data indicates that dizziness is an uncommon side effect reported by some users. While tiredness or fatigue is not frequently listed as an official side effect, you may still experience these symptoms. If you have concerns about fatigue, contact your healthcare provider.

Q: Does Amcik interact with any common supplements like vitamins or herbal products?

Official drug labels list specific interactions with certain prescription medications and advise taking the drug with food, but they do not typically document specific interactions with common vitamins or herbal products. It is important for patients to discuss all supplements, vitamins, and herbal products they are taking with a healthcare professional.

Q: Can children or teenagers be prescribed Amcik?

Yes, Amcik has established use in pediatric patients who are three months of age or older. Specific dosing guidelines are used for children weighing less than 40 text kg, while those weighing 40 text kg or more typically follow the standard protocol.

Q: Does Amcik have a risk of causing allergic reactions?

Yes, regulatory documents contain a serious warning regarding the risk of hypersensitivity reactions (severe allergic reactions) which can be fatal. The highest risk is associated with individuals who have a known history of allergy to penicillin-type drugs or other beta-lactam agents.

Q: What are the signs that my body is not agreeing with Amcik?

Signs that warrant attention include severe diarrhea, especially if bloody or watery, which can signal a serious gut infection, as well as yellowing of the skin or eyes (jaundice). Other serious signs include severe rash, blistering of the skin, or difficulty breathing, which may signal a serious allergic reaction.

Q: Can Amcik affect the results of blood tests?

Official product information notes that Amoxicillin may interfere with certain laboratory tests. Specifically, it can cause false-positive results on non-enzymatic urine glucose tests and may also cause a false-positive Coombs test.

Q: Is it better to take Amcik in the morning or at night?

The most important administration instruction is that Amcik must be taken at the start of a meal to enhance absorption and reduce potential stomach discomfort. Official labeling does not specify whether morning or night is preferred, as long as the dose is taken with food and at the correct time interval.

Q: What should I do if I forget to take my scheduled dose of Amcik?

Regulatory information advises that a missed dose may be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. It is advised not to take two doses at once to make up for a missed dose.

Q: Does Amcik lose its effectiveness over time if it's nearing its expiration date?

Regulatory guidance advises against using any medicine past its expiration date. This is because the effectiveness of the active ingredients cannot be guaranteed once they have exceeded the labeled shelf life.

Q: Is there a generic version of Amcik available yet?

Yes, the combination of active ingredients, formally known as Amoxicillin and Clavulanate Potassium, is widely available in generic formulations.

Q: Can Amcik be split in half if the pill is large?

Certain formulations, such as the extended-release tablets, must be swallowed whole and should not be crushed or chewed. Generally, tablets should not be split unless they are clearly scored and a healthcare professional has advised it.

Q: Is there a liquid form of Amcik for people who have trouble swallowing pills?

Yes, the medication is available as a powder for oral suspension which is a liquid form. This preparation is typically used for pediatric patients but may be an option for others who have difficulty swallowing tablets.

Q: What is the 'half-life' of the drug Amcik?

The half-life refers to the time it takes for the amount of drug in the body to be reduced by half. For the amoxicillin component, the terminal half-life is approximately 1.27 text hours, and for clavulanate, it is approximately 1.03 text hours in a specific formulation.

Q: Does Amcik have a known impact on mental clarity or focus?

Official information lists dizziness as an uncommon side effect. Rare, serious effects on the Central Nervous System, such as convulsions, have also been reported, particularly in patients with kidney impairment. These effects could impact focus or clarity.

Q: Can taking Amcik affect my ability to drive or operate machinery?

Official warnings often note that due to potential side effects like dizziness or, rarely, convulsions, the ability to drive or operate complex machinery may be affected. Patients should be cautious until they understand how the medication affects them.

Q: Is it okay to stop taking Amcik as soon as I feel better?

Official guidance advises that patients should complete the full prescribed course of therapy, even if symptoms begin to improve quickly. Stopping early may increase the risk of developing drug resistance.

Q: What are the possible symptoms if someone accidentally takes too much Amcik?

Symptoms of taking too much Amcik may include nausea, vomiting, stomach pain, diarrhea, and decreased urination. Severe overdose can potentially lead to kidney problems.

Q: Can Amcik cause changes in mood or sleep patterns?

Official adverse reaction reports include rare occurrences of convulsions and hyperactivity. General changes to mood or sleep patterns are not commonly listed as frequent side effects.

Q: What is the mechanism by which Amcik interacts with alcohol?

Official product information does not document a specific direct chemical interaction between Amcik and alcohol. However, alcohol may increase the risk or severity of certain known side effects, such as nausea or vomiting, or lead to general unwellness.

Q: Why is close monitoring by a doctor required when starting Amcik?

Close monitoring is required due to the risk of rare but serious adverse effects, including hypersensitivity reactions and possible hepatic dysfunction (liver issues). Additionally, patients with existing kidney impairment require specific monitoring for dose adjustment.

Q: Does body weight influence the way Amcik works in a person?

Yes. For children, the dosage is determined by a weight-based scale (mg/kg). For patients weighing 40 text kg and over, the drug is dosed according to the established adult guidelines.

Q: Is Amcik generally considered a well-tolerated medication?

Based on regulatory data, Amcik is generally considered a well-tolerated medication. The most frequently reported side effects, such as diarrhea, nausea, and rash, are usually mild to moderate and temporary.

How should Amcik be stored and disposed of?

How to Store and Dispose of Amcik

Official storage conditions for Amcik (Amoxicillin and Clavulanate Potassium) vary based on the pharmaceutical form.

Storage Requirements

Item Official Regulatory Requirement
Dry Product (Tablets/Powder) Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Reconstituted Oral Suspension Must be refrigerated at 2 C to 8 C (36 F to 46 F). DO NOT FREEZE.
Stability Limit The reconstituted suspension must be discarded after 10 days.

All forms must be kept in the original, tightly closed container and protected from excess heat and moisture. The medicine must be kept out of the reach of children.

Disposal

Unused or expired Amcik should be disposed of safely following federal guidelines, such as utilizing a drug take-back program. If a take-back program is unavailable, follow approved household trash disposal procedures, ensuring the medicine is mixed with an undesirable substance and sealed before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amcik found in:

A-Z Index: